Key Points
- CEO Robert Blum sold 7,500 Cytokinetics shares for approximately $471,600 under a pre-arranged Rule 10b5-1 plan, reducing his direct ownership by 2.62% to 278,544 shares.
- Cytokinetics shares opened at $61.62, down 1.9%, while the company reported a quarterly loss of $1.50 per share and $28.62 million in revenue; revenue declined 57.1% year over year.
- Analysts maintain a generally positive outlook, with 18 Buy ratings, one Hold, and one Sell, producing a “Moderate Buy” consensus and an average price target of $106.06. Recent aficamten clinical data also provided potential support for the company’s long-term pipeline prospects.
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert Blum sold 7,500 shares of Cytokinetics stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $62.88, for a total value of $471,600.00. Following the sale, the chief executive officer directly owned 278,544 shares in the company, valued at $17,514,846.72. The trade was a 2.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Cytokinetics Trading Down 1.9%
CYTK stock opened at $61.62 on Wednesday. Cytokinetics, Incorporated has a 1-year low of $54.30 and a 1-year high of $88.31. The firm has a market cap of $7.67 billion, a P/E ratio of -8.53 and a beta of 0.41. The business's 50 day moving average is $71.13 and its 200-day moving average is $73.27.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.63) by $0.13. The company had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. The company's quarterly revenue was down 57.1% on a year-over-year basis. During the same period in the previous year, the company posted ($1.12) earnings per share. Sell-side analysts forecast that Cytokinetics, Incorporated will post -5.98 EPS for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on CYTK. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cytokinetics in a research report on Friday, July 17th. Needham & Company LLC increased their price objective on Cytokinetics from $102.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Barclays lifted their price objective on Cytokinetics from $95.00 to $110.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Royal Bank Of Canada boosted their target price on shares of Cytokinetics from $112.00 to $113.00 and gave the company an "outperform" rating in a research note on Thursday, October 8th. Finally, HC Wainwright restated a "buy" rating and issued a $140.00 target price on shares of Cytokinetics in a research note on Monday, August 31st. Eighteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $106.06.
Read Our Latest Stock Analysis on CYTK
Institutional Trading of Cytokinetics
Several hedge funds have recently modified their holdings of CYTK. Mirador Capital Partners LP raised its stake in shares of Cytokinetics by 3.2% in the third quarter. Mirador Capital Partners LP now owns 208,896 shares of the biopharmaceutical company's stock valued at $13,768,000 after acquiring an additional 6,526 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Cytokinetics by 8.6% in the 3rd quarter. GAMMA Investing LLC now owns 2,700 shares of the biopharmaceutical company's stock worth $178,000 after acquiring an additional 213 shares in the last quarter. Cim Investment Management Inc. boosted its holdings in shares of Cytokinetics by 20.9% in the 2nd quarter. Cim Investment Management Inc. now owns 5,657 shares of the biopharmaceutical company's stock worth $482,000 after acquiring an additional 979 shares in the last quarter. Tidal Investments LLC boosted its holdings in shares of Cytokinetics by 24.7% in the 2nd quarter. Tidal Investments LLC now owns 24,921 shares of the biopharmaceutical company's stock worth $2,123,000 after acquiring an additional 4,938 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new stake in Cytokinetics during the 2nd quarter worth approximately $774,000.
Cytokinetics News Summary
Here are the key news stories impacting Cytokinetics this week:
- Positive Sentiment: Additional analyses from the Phase 3 ACACIA-HCM study further characterized aficamten’s effects across exercise-performance measures and patient responder groups. The data also supported the drug’s dose-adjustment approach and safety profile, potentially strengthening Cytokinetics’ case for aficamten as a future treatment for non-obstructive HCM. Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
- Positive Sentiment: Several market commentaries highlighted the Phase 3 aficamten results and the possibility that the drug’s multi-domain benefits could improve Cytokinetics’ long-term commercial outlook. The company’s pipeline and potential heart-drug opportunity are driving the fresh investor interest, although regulatory and commercialization risks remain. Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten in NHCM
- Neutral Sentiment: Wall Street Zen upgraded Cytokinetics to a “Hold,” suggesting a more balanced view of the shares after the recent clinical updates rather than a clearly bullish or bearish shift. Wall Street Zen Upgrades Cytokinetics to Hold
- Neutral Sentiment: Chief Executive Officer Robert I. Blum sold 7,500 shares for approximately $471,600 under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled in advance and he retained 278,544 shares, it is a limited signal of insider sentiment, though it may add modest pressure to investor perception. SEC Form 4 Filing
About Cytokinetics
(
Get Free Report)
Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.
Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
